Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mustang Bio Inc (MBIO)
NASDAQ:MBIO
Holding MBIO?
Track your performance easily
MBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.13 - $1.68
Previous Close$0.21
Volume412.55K
Average Volume (3M)1.86M
Market Cap
$9.80M
Enterprise Value$7.26M
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)$983.00K
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Mar 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding47,780,248
10 Day Avg. Volume1,248,729
30 Day Avg. Volume1,864,256
Standard Deviation0.29
R-Squared0.12
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-1.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Mustang Bio News
PremiumCompany Announcements
Mustang Bio Faces Nasdaq Delisting and Leadership Changes
PremiumPre-Earnings
Is MBIO a Buy, Before Earnings?
PremiumCompany Announcements
Mustang Bio Secures $4M through Strategic Warrant Agreement
Ownership Overview
5.50% Insiders
0.34% Mutual Funds
0.37% Other Institutional Investors
93.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.13 and its highest was $1.68 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Currently, no data Available
When is Mustang Bio Inc’s upcoming earnings report date?
Mustang Bio Inc’s upcoming earnings report date is Mar 24, 2025 which is in 120 days.
How were Mustang Bio Inc’s earnings last quarter?
Mustang Bio Inc released its earnings results on Nov 12, 2024. The company reported -$0.038 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.092.
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 46,934,864 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Mustang Bio Inc reported an EPS of -$0.038 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
---
Mustang Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-65.03%
Trailing 12-Months
Company Description
Mustang Bio Inc
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.
---
MBIO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Adverum Biotechnologies
―
TRACON Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering MBIO
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-66.18%
reiterated a buy rating 9 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -66.18% per trade.
---